Blog
RSS FeedPosted by Michael Wonder on 09 May 2026
Lilly's Retevmo moves closer to Korea reimbursement coverage after key review approval
8 May 2026 - Retevmo (selpercatinib), a targeted therapy for RET gene mutation-driven cancers, has cleared a major hurdle toward ...
Posted by Michael Wonder on 08 May 2026
Korea begins insurance coverage for Novo Nordisk’s weekly growth hormone drug
6 May 2026 - Some children and adults in Korea with growth hormone deficiency can now receive Novo Nordisk’s once ...
Posted by Michael Wonder on 08 May 2026
AZ's Imfinzi wins reimbursement for first-line BTC, HCC treatment in Korea
3 March 2026 - AstraZeneca Korea said Tuesday that Imfinzi (durvalumab) is now covered by national health insurance as of ...
Posted by Michael Wonder on 04 May 2026
Korea covers Takeda’s Takhzyro, but most patients may still be left out: experts
26 March 2026 - Korea has granted reimbursement for Takeda’s hereditary angioedema drug Takhzyro (lanadelumab), but physicians say most patients ...
Posted by Michael Wonder on 06 Apr 2026
Padcev, Tavneos clear key step toward reimbursement in Korea
3 April 2026 - Astellas Pharma Korea’s Padcev (enfortumab vedotin) for urothelial carcinoma and Meditip’s Tavneos (avacopan) for rare vasculitides ...
Posted by Michael Wonder on 04 Apr 2026
US hikes tariffs on Korean patented drugs, spares biosimilars for year
3 April 2026 - Korean drug makers eye US manufacturing labels and limited exemptions as Washington targets patented meds with new ...
Posted by Michael Wonder on 02 Apr 2026
AbbVie's Epkinly gets health insurance coverage for DLBCL in Korea
1 April 2026 - AbbVie Korea said Wednesday that its bispecific antibody Epkinly (epcoritamab), will receive national health insurance coverage ...
Posted by Michael Wonder on 31 Mar 2026
Roche Korea to launch reimbursed Vabysmo pre-filled syringe in April, expanding retinal treatment options
30 March 2026 - Roche Korea said Monday that the Ministry of Health and Welfare has approved national health insurance ...
Posted by Michael Wonder on 12 Mar 2026
Health ministry cautious on timing of generic drug price cuts, reaffirms ‘no-exception’ principle
11 March 2026 - Amid mounting opposition from the pharmaceutical industry over the government's proposed “drug pricing system improvement plan,” ...
Posted by Michael Wonder on 06 Mar 2026
Roche's Columvi, Takeda's Fruzaqla pass first review for Korea insurance coverage
5 March 2026 - Roche's DLBCL treatment Columvi (glofitamab) and Takeda's metastatic colorectal cancer treatment Fruzaqla (fruquintinib) have cleared the ...
Posted by Michael Wonder on 04 Mar 2026
J&J Korea receives reimbursement for Balversa in urothelial carcinoma
3 March 2026 - Johnson & Johnson Innovative Medicine Korea said it received reimbursement for Balversa (erdafitinib), a treatment for ...
Posted by Michael Wonder on 03 Mar 2026
Xpovio receives reimbursement approval in South Korea for a second multiple myeloma indication
1 March 2026 - Antengene announced that South Korea's National Health Insurance Service has approved the reimbursement of Xpovio (selinexor) in ...
Posted by Michael Wonder on 03 Mar 2026
Expanded reimbursement for Roche Korea’s Evrysdi broadens access for SMA patients
3 March 2026 - Roche Korea said the expanded health insurance coverage and updated reimbursement criteria for the oral spinal ...
Posted by Michael Wonder on 18 Feb 2026
Novo’s Ozempic wins reimbursement in Korea but strict criteria limit early access
12 February 2026 - The entry of Novo Nordisk's GLP-1 receptor agonist Ozempic (semaglutide) into the Korean reimbursement market marks ...
Posted by Michael Wonder on 12 Feb 2026
Pharma group warns drug price cuts threaten industry investment
10 February 2026 - KPBMA demands postponement, impact assessments, and policy dialogue to protect R&D and health security amid pricing reforms. ...